

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



10 SFP 2018

FDA ADVISORY No. 2018-275

TO:

GENERAL CONSUMING PUBLIC

SUBJECT:

Public Health Warning Against the Use of Cosmetic

Product Containing Banned Ingredient/s (Batch 9)

The Food and Drug Administration (FDA) advises the public against the purchase and use of the adulterated cosmetic product BEAUCHE REJUVENATING CREAM which tested positive for the presence of HYDROQUINONE and TRETINOIN, ingredients that are not allowed to be part of a cosmetic (refer to the image below for the product particulars/details):

PRODUCT DETAILS

Manufactured by:

Beauché International by Conchita Inc.

Manufacturer's Address: Block 6 Lot 9-11, Dasmariñas Technopark, Brgy. Paliparan I, Dasmariñas, Cavite, Philippines 4114

Local Company Responsible for Placing the Product in the Market: Beauché International by Conchita Inc.

Address:

Block 6 Lot 9-11, Dasmariñas Technopark, Brgy. Paliparan I, Dasmariñas, Cavite, Philippines 4114

Country of Manufacture: **Philippines**

Lot Number: 2715173926 Manufacturing Date: 260917 Expiry Date: 260919



Products containing Hydroquinone and/or Tretinoin (Retinoic Acid) shall be classified as home remedy, over-the-counter, or prescription drug depending on the amount present as per Administrative Order No. 13 s. 1999.

Accordingly, because these products are not compliant with the existing standards, consumers should be vigilant against their purchase and use. The use of these products can pose potential health hazards to the consuming public and may result to adverse reactions including but not limited to skin irritation, itchiness, anaphylactic shock and organ failure.

Civic Drive, Filinvest City, Alabang 1781 Muntinlupa, Philippines Trunk Line +63 2 857 1900 Fax +63 2 807 0751 Website: www.fda.gov.ph Email: info@fda.gov.ph



The public is advised to be vigilant against cosmetic products that might not be duly notified with FDA. Always check if a cosmetic product has been notified with FDA before purchasing it by making use of the embedded *Search* feature of the FDA website accessible at www.fda.gov.ph.

All concerned establishments are warned not to distribute the above-identified violative cosmetic products, otherwise, regulatory actions and sanctions shall be strictly pursued.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of the above violative cosmetic products, utilize our online reporting facility, eReport, at www.fda.gov.ph/ereport, or e-mail us via report@fda.gov.ph, or call us at the Center for Cosmetics Regulation and Research (CCRR) hotline (02) 857-1900 local 8113 or 8107.

Dissemination of the information to all concerned is requested.

NELA CHARADE G. PUNO, RPh

Director General

